UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2090-14
Program Prior Authorization/Medical Necessity
Medication Epclusa® (sofosbuvir/velpatasvir)
P&T Approval Date 5/2016, 8/2016, 12/2016, 9/2017, 11/2018, 11/2019, 11/2020, 5/2021,
8/2021, 8/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Epclusa (sofosbuvir/velpatasvir) is a fixed-dose combination of sofosbuvir, a hepatitis C virus
(HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor,
and is indicated for the treatment of adult patients and pediatric patients 3 years of age and older
with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection: 1
• without cirrhosis or with compensated cirrhosis
• with decompensated cirrhosis for use in combination with ribavirin
2. Coverage Criteriaa:
A. For the treatment of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection, Epclusa will be
approved based on all of the following criteria:
1. Diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection
-AND-
2. One of the following:
a. Patient does not have decompensated liver disease (e.g., Child-Pugh Class B or C)
-OR-
b. Both of the following:
(1) Patient has decompensated liver disease (e.g., Child-Pugh Class B or C)
-AND-
(2) Used in combination with ribavirin
-AND-
3. Patient is not receiving Epclusa in combination with another HCV direct acting antiviral
agent [e.g., Mavyret (glecaprevir/pibrentasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi
(sofosbuvir), Zepatier (elbasvir/grazoprevir)]
© 2024 UnitedHealthcare Services Inc.
1
-AND-
4. Physician/provider asserts patient demonstrates treatment readiness, including the
ability to adhere to the treatment regimen
Authorization will be issued for 12 weeks.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Epclusa [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2022.
2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of
America. Recommendations for Testing, Managing, and Treating Hepatitis C.
https://www.hcvguidelines.org/. Accessed June 5, 2024.
Program Prior Authorization/Medical Necessity – Epclusa
(sofosbuvir/velpatasvir)
Change Control
Date Change
5/2016 New program.
8/2016 Added step requirement of Harvoni for genotypes 1, 4, 5 or 6 infection.
11/2016 Added California coverage information.
12/2016 Removed abstinence-based criteria and replaced with treatment
readiness screening criteria. Added Maryland, Indiana and West
Virginia coverage information.
5/2017 Administrative update to reorder criteria. State mandate reference
language updated.
9/2017 Revised step therapy criteria based on new product availability,
included NY prescriber requirement, removed treatment readiness
screening tools and removed medical record submission requirements.
11/2018 Annual update with no changes to the criteria. Updated references.
11/2019 Annual update with no changes to the criteria. Updated references.
11/2020 Annual review. Updated background with no changes to clinical
criteria. Updated references.
5/2021 Removed prescriber requirement. Updated references.
© 2024 UnitedHealthcare Services Inc.
2
8/2021 Updated background with no changes to clinical criteria. Updated
references.
8/2022 Annual review. Added Child-Pugh classes for decompensated cirrhosis.
Updated references.
7/2023 Annual review. Updated order of criteria without change to clinical
intent. Updated references.
7/2024 Annual review. Removed liver disease staging criteria that was included
for quality purposes rather than part of coverage decision. Updated
references.
© 2024 UnitedHealthcare Services Inc.
3